GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 205 filers reported holding GENMAB A/S in Q3 2021. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,200,037 | +320.8% | 62,377 | +353.5% | 0.00% | +300.0% |
Q2 2023 | $522,789 | +0.2% | 13,754 | -0.4% | 0.00% | 0.0% |
Q1 2023 | $521,654 | -40.4% | 13,815 | -33.1% | 0.00% | -50.0% |
Q4 2022 | $875,105 | +32.2% | 20,649 | +0.3% | 0.00% | +100.0% |
Q3 2022 | $662,000 | +35.7% | 20,578 | +37.1% | 0.00% | 0.0% |
Q2 2022 | $488,000 | -17.8% | 15,010 | -8.6% | 0.00% | 0.0% |
Q1 2022 | $594,000 | -21.4% | 16,418 | -14.1% | 0.00% | 0.0% |
Q4 2021 | $756,000 | -18.1% | 19,111 | -9.5% | 0.00% | -50.0% |
Q3 2021 | $923,000 | +43.3% | 21,114 | +33.9% | 0.00% | +100.0% |
Q2 2021 | $644,000 | +8.6% | 15,763 | -12.7% | 0.00% | 0.0% |
Q1 2021 | $593,000 | -10.4% | 18,057 | +10.9% | 0.00% | 0.0% |
Q4 2020 | $662,000 | +14.1% | 16,287 | +2.7% | 0.00% | 0.0% |
Q3 2020 | $580,000 | -5.4% | 15,862 | -12.3% | 0.00% | 0.0% |
Q2 2020 | $613,000 | +115.8% | 18,095 | +35.0% | 0.00% | 0.0% |
Q1 2020 | $284,000 | +19.8% | 13,408 | +26.2% | 0.00% | – |
Q4 2019 | $237,000 | – | 10,626 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |